

# Jakub GoÅ,Äb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3750740/publications.pdf>

Version: 2024-02-01

164  
papers

13,722  
citations

87401

40  
h-index

24511

114  
g-index

169  
all docs

169  
docs citations

169  
times ranked

25932  
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax. <i>Oncogene</i> , 2022, 41, 1600-1609.	2.6	9
2	Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis. <i>European Journal of Pharmacology</i> , 2022, 919, 174792.	1.7	10
3	The Influence of Time of Day of Vaccination with BNT162b2 on the Adverse Drug Reactions and Efficacy of Humoral Response against SARS-CoV-2 in an Observational Study of Young Adults. <i>Vaccines</i> , 2022, 10, 443.	2.1	11
4	Evaluation of the Antitumor Immune Response Following Photofrin-Based PDT in Combination with the Epigenetic Agent 5-Aza-2-Deoxycytidine. <i>Methods in Molecular Biology</i> , 2022, 2451, 559-567.	0.4	1
5	Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. <i>OncolImmunology</i> , 2021, 10, 1956143.	2.1	30
6	Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development. <i>Cancers</i> , 2021, 13, 870.	1.7	28
7	Can Developments in Tissue Optical Clearing Aid Super-Resolution Microscopy Imaging?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6730.	1.8	2
8	The role of CD71+ erythroid cells in the regulation of the immune response. , 2021, 228, 107927.		37
9	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. <i>Cancer Research</i> , 2021, 81, 6029-6043.	0.4	20
10	Potent but transient immunosuppression of T-cells is a general feature of CD71+ erythroid cells. <i>Communications Biology</i> , 2021, 4, 1384.	2.0	12
11	Discovery of <b>OATD-01</b>, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15527-15540.	2.9	18
12	A New Inhibitor of Tubulin Polymerization Kills Multiple Cancer Cell Types and Reveals p21-Mediated Mechanism Determining Cell Death after Mitotic Catastrophe. <i>Cancers</i> , 2020, 12, 2161.	1.7	10
13	Myeloid Cell-Derived Arginase in Cancer Immune Response. <i>Frontiers in Immunology</i> , 2020, 11, 938.	2.2	249
14	Discovery and Pharmacokinetics of Sulfamides and Guanidines as Potent Human Arginase 1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 433-438.	1.3	27
15	Immunoglobulin expression and the humoral immune response is regulated by the non-canonical poly(A) polymerase TENT5C. <i>Nature Communications</i> , 2020, 11, 2032.	5.8	34
16	Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1101-1112.	2.0	13
17	Systematic Evaluation of Chemically Distinct Tissue Optical Clearing Techniques in Murine Lymph Nodes. <i>Journal of Immunology</i> , 2020, 204, 1395-1407.	0.4	10
18	Tissue clearing-based method for unobstructed three-dimensional imaging of mouse penis with subcellular resolution. <i>Journal of Biophotonics</i> , 2020, 13, e202000072.	1.1	1

#	ARTICLE	IF	CITATIONS
19	Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase. ACS Medicinal Chemistry Letters, 2020, 11, 1228-1235.	1.3	9
20	Bone marrow is the preferred site of memory CD4+ T cell proliferation during recovery from sepsis. JCI Insight, 2020, 5, .	2.3	16
21	Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies. Blood, 2020, 136, 33-34.	0.6	0
22	Pharmacological Induction of NOXA Sensitizes High-Risk B Cell Acute Lymphoblastic Leukemia Cells to Venetoclax. Blood, 2020, 136, 17-18.	0.6	0
23	Development of Dual Chitinase Inhibitors as Potential New Treatment for Respiratory System Diseases. Journal of Medicinal Chemistry, 2019, 62, 7126-7145.	2.9	22
24	Advances in Ex Situ Tissue Optical Clearing. Laser and Photonics Reviews, 2019, 13, 1800292.	4.4	52
25	Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nature Communications, 2019, 10, 3000.	5.8	194
26	Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response. Oncoimmunology, 2019, 8, e1655370.	2.1	9
27	The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies. PLoS ONE, 2019, 14, e0210796.	1.1	9
28	Targeting the thioredoxin system as a novel strategy against Bâ€cell acute lymphoblastic leukemia. Molecular Oncology, 2019, 13, 1180-1195.	2.1	24
29	Cholesterol restricts lymphotoxin Î² receptor-triggered NF-Î²B signaling. Cell Communication and Signaling, 2019, 17, 171.	2.7	16
30	Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. Oncogene, 2019, 38, 2860-2875.	2.6	19
31	Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate. Redox Biology, 2019, 21, 101062.	3.9	29
32	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology, 2018, 7, e1423183.	2.1	23
33	Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 310-314.	1.0	13
34	Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma. Journal of Medicinal Chemistry, 2018, 61, 695-710.	2.9	23
35	Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy. BMC Cancer, 2018, 18, 210.	1.1	36
36	Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. British Journal of Cancer, 2018, 119, 873-884.	2.9	49

#	ARTICLE	IF	CITATIONS
37	Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2018, 6, 930-940.	1.6	21
38	Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. <i>Haematologica</i> , 2018, 103, 1843-1852.	1.7	8
39	HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. <i>Blood</i> , 2017, 130, 1628-1638.	0.6	40
40	Selection of an optimal promoter for gene transfer in normal B cells. <i>Molecular Medicine Reports</i> , 2017, 16, 3041-3048.	1.1	6
41	Photochemical delivery of bleomycin induces T-cell activation of importance for curative effect and systemic anti-tumor immunity. <i>Journal of Controlled Release</i> , 2017, 268, 120-127.	4.8	17
42	Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice. <i>European Journal of Cancer</i> , 2017, 83, 19-27.	1.3	39
43	Investigation of cell death mechanisms in human lymphatic endothelial cells undergoing photodynamic therapy. <i>Photodiagnosis and Photodynamic Therapy</i> , 2016, 14, 57-65.	1.3	12
44	The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development. <i>Oncotarget</i> , 2016, 5, e1182278.	2.1	31
45	Dissection of CD20 regulation in lymphoma using RNAi. <i>Leukemia</i> , 2016, 30, 2409-2412.	3.3	13
46	Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo. <i>Oncology Reports</i> , 2016, 35, 3151-3158.	1.2	4
47	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>PLoS ONE</i> , 2016, 11, e0155893.	1.1	26
48	Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. <i>Oncotarget</i> , 2016, 7, 1717-1731.	0.8	48
49	Adenanthin, a new inhibitor of thiolâ€dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. <i>Immunology</i> , 2015, 146, 173-183.	2.0	16
50	Review Cancer stem cells in haematological malignancies. <i>Wspolczesna Onkologia</i> , 2015, 1A, 1-6.	0.7	15
51	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	2.2	317
52	Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity. <i>Frontiers in Oncology</i> , 2015, 5, 176.	1.3	25
53	Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins. <i>Blood Cancer Journal</i> , 2015, 5, e300-e300.	2.8	4
54	SK053 triggers tumor cells apoptosis by oxidative stress-mediated endoplasmic reticulum stress. <i>Biochemical Pharmacology</i> , 2015, 93, 418-427.	2.0	26

#	ARTICLE	IF	CITATIONS
55	Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surface-Associated Calreticulin. <i>Cancer Research</i> , 2015, 75, 1603-1614.	0.4	86
56	Melanoma targeting with the loco-regional chemotherapeutic, Melphalan: From cell death to immunotherapeutic efficacy. <i>Oncolmmunology</i> , 2015, 4, e1054600.	2.1	4
57	GRP78-targeting Sensitizes Cancer Cells to Cytotoxic Effects of Photodynamic Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 149-161.	0.1	0
58	MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>Blood</i> , 2015, 126, 4917-4917.	0.6	0
59	Epigenetic remodeling combined with photodynamic therapy elicits anticancer immune responses. <i>Oncolmmunology</i> , 2014, 3, e28837.	2.1	10
60	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. <i>MABs</i> , 2014, 6, 1300-1313.	2.6	16
61	Statins impair glucose uptake in human cells. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000017.	1.2	37
62	Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model. <i>Translational Oncology</i> , 2014, 7, 570-579.	1.7	17
63	Adenanthin targets proteins involved in the regulation of disulphide bonds. <i>Biochemical Pharmacology</i> , 2014, 89, 210-216.	2.0	36
64	Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis. <i>Angiogenesis</i> , 2014, 17, 347-357.	3.7	29
65	Iron Chelators in Photodynamic Therapy Revisited: Synergistic Effect by Novel Highly Active Thiosemicarbazones. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 336-339.	1.3	30
66	B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. <i>Leukemia</i> , 2014, 28, 1163-1167.	3.3	54
67	5-Aza-2â€²-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. <i>European Journal of Cancer</i> , 2014, 50, 1370-1381.	1.3	56
68	Danger signalling during cancer cell death: origins, plasticity and regulation. <i>Cell Death and Differentiation</i> , 2014, 21, 26-38.	5.0	187
69	Peroxiredoxins-1 and 2 Affect Proliferation and Survival of Lymphoma Cells. <i>Blood</i> , 2014, 124, 1693-1693.	0.6	1
70	Exploring the Anti-Cancer Activity of Novel Thiosemicarbazones Generated through the Combination of Retro-Fragments: Dissection of Critical Structure-Activity Relationships. <i>PLoS ONE</i> , 2014, 9, e110291.	1.1	61
71	HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies. <i>Blood</i> , 2014, 124, 3641-3641.	0.6	0
72	SK053, an Inhibitor of Enzymes Involved in Allosteric Disulfide Bonds Formation, Targets Expression of Histone Genes and Induces Differentiation of Human AML Cell. <i>Blood</i> , 2014, 124, 3503-3503.	0.6	0

#	ARTICLE	IF	CITATIONS
73	GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. <i>Cell Death and Disease</i> , 2013, 4, e741-e741.	2.7	52
74	Inhibitors Of Src Family and AKT Regulate The Activity Of CD20 Promoter. <i>Blood</i> , 2013, 122, 1838-1838.	0.6	1
75	HDAC6 Inhibition Increases CD20 Level and Improves The Efficacy Of Anti-CD20 Monoclonal Antibodies. <i>Blood</i> , 2013, 122, 4406-4406.	0.6	1
76	Inhibitors Of B-Cell Receptor Molecules Affect Surface CD20 and Impair Antitumor Activity Of Anti-CD20 Monoclonal Antibodies. <i>Blood</i> , 2013, 122, 4217-4217.	0.6	0
77	SK053 An Inhibitor Of Enzymes Involved In Allosteric Disulfide Bonds Formation Induces Differentiation Of Human AML Cells. <i>Blood</i> , 2013, 122, 4215-4215.	0.6	0
78	Contribution of ER Stress to Immunogenic Cancer Cell Death. , 2012, , 413-428.		2
79	Application of a proteomic approach to identify proteins associated with primary graft non-function after liver transplantation. <i>International Journal of Molecular Medicine</i> , 2012, 30, 755-764.	1.8	8
80	A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. <i>EMBO Journal</i> , 2012, 31, 1062-1079.	3.5	641
81	Statins Impair Glucose Uptake in Tumor Cells. <i>Neoplasia</i> , 2012, 14, 311-323.	2.3	37
82	Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity. <i>Journal of Biological Chemistry</i> , 2012, 287, 31983-31993.	1.6	19
83	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
84	Studies toward Novel Peptidomimetic Inhibitors of Thioredoxinâ€“Thioredoxin Reductase System. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 55-67.	2.9	44
85	Drug delivery technologies and immunological aspects of photodynamic therapy. <i>Photochemical and Photobiological Sciences</i> , 2011, 10, 647-648.	1.6	11
86	Interleukin 15 as a promising candidate for tumor immunotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2011, 22, 99-108.	3.2	102
87	Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer. <i>Molecules</i> , 2011, 16, 4140-4164.	1.7	198
88	Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 277.	3.0	40
89	Antitumor effects of the combination of cholesterol reducing drugs. <i>Oncology Reports</i> , 2011, 26, 169-76.	1.2	7
90	Photodynamic therapy of cancer: An update. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 250-281.	157.7	3,902

#	ARTICLE	IF	CITATIONS
91	PDT-induced inflammatory and host responses. <i>Photochemical and Photobiological Sciences</i> , 2011, 10, 653-663.	1.6	76
92	Sorafenib Affects Membrane Complement Inhibitors and Improves Antitumor Activity of Rituximab,. <i>Blood</i> , 2011, 118, 3723-3723.	0.6	0
93	Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,. <i>Blood</i> , 2011, 118, 3722-3722.	0.6	0
94	Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels. <i>Blood</i> , 2011, 118, 1661-1661.	0.6	0
95	Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. <i>Blood</i> , 2010, 115, 3745-3755.	0.6	40
96	Genetic Modification of T Cells Improves the Effectiveness of Adoptive Tumor Immunotherapy. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 347-354.	1.0	2
97	Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010, 15, 1050-1071.	2.2	253
98	Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1805, 53-71.	3.3	292
99	Statins can modulate effectiveness of antitumor therapeutic modalities. <i>Medicinal Research Reviews</i> , 2010, 30, 102-135.	5.0	37
100	Proteolytic pathways involved in modulation of CD20 levels. <i>Autophagy</i> , 2010, 6, 810-812.	4.3	4
101	Studies of the Synthesis of All Stereoisomers of MG-132 Proteasome Inhibitors in the Tumor Targeting Approach. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1509-1518.	2.9	38
102	Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib. <i>American Journal of Pathology</i> , 2010, 176, 2658-2668.	1.9	115
103	Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. <i>Cancer Letters</i> , 2010, 288, 57-67.	3.2	34
104	Photodynamic therapy-driven induction of suicide cytosine deaminase gene. <i>Cancer Letters</i> , 2010, 290, 216-222.	3.2	7
105	Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response. <i>Cancer Research</i> , 2009, 69, 4235-4243.	0.4	96
106	Improvement of anti-tumor activity of photodynamic therapy through inhibition of cytoprotective mechanism in tumor cells. , 2009, , .		1
107	The possible role of factor H in colon cancer resistance to complement attack. <i>International Journal of Cancer</i> , 2008, 122, 2030-2037.	2.3	44
108	Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. <i>BMC Cancer</i> , 2008, 8, 197.	1.1	59

#	ARTICLE	IF	CITATIONS
109	Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20. <i>PLoS Medicine</i> , 2008, 5, e64.	3.9	115
110	Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells. <i>International Journal of Oncology</i> , 2007, 31, 1547-52.	1.4	3
111	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. <i>International Journal of Oncology</i> , 2007, , .	1.4	6
112	Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 731-741.	2.2	119
113	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. <i>International Journal of Oncology</i> , 2007, 30, 1413-25.	1.4	8
114	Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. <i>Oncogene</i> , 2006, 25, 3365-3374.	2.6	163
115	Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway. <i>Oncology Reports</i> , 2006, 16, 1273.	1.2	7
116	Combined Effect of Proteasome and Calpain Inhibition on Cisplatin-Resistant Human Melanoma Cells. <i>Cancer Research</i> , 2006, 66, 7598-7605.	0.4	43
117	Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in vitro and in vivo studies. <i>International Journal of Cancer</i> , 2005, 117, 59-67.	2.3	40
118	Topical ALA-ALA-PDT modifies neutrophils' chemiluminescence, lymphocytes' interleukin-1beta secretion and serum level of transforming growth factor beta1 in patients with nonmelanoma skin malignancies. <i>Photodiagnosis and Photodynamic Therapy</i> , 2005, 2, 65-72.	1.3	13
119	The influence of photodynamic therapy on the immune response. <i>Photodiagnosis and Photodynamic Therapy</i> , 2005, 2, 283-298.	1.3	83
120	Prospects for p53-based cancer therapy.. <i>Acta Biochimica Polonica</i> , 2005, 52, 321-328.	0.3	21
121	Direct tumor damage mechanisms of photodynamic therapy.. <i>Acta Biochimica Polonica</i> , 2005, 52, 339-352.	0.3	222
122	Direct tumor damage mechanisms of photodynamic therapy. <i>Acta Biochimica Polonica</i> , 2005, 52, 339-52.	0.3	63
123	CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice. <i>Clinical Cancer Research</i> , 2004, 10, 4165-4175.	3.2	35
124	Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. <i>International Journal of Oncology</i> , 2004, 24, 1149.	1.4	17
125	AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. <i>Leukemia Research</i> , 2004, 28, 53-61.	0.4	4
126	Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2004, 9, 193-204.	2.2	5



#	ARTICLE	IF	CITATIONS
127	Role of the ubiquitinâ€“proteasome pathway in the diagnosis of human diseases. <i>Clinica Chimica Acta</i> , 2004, 340, 27-40.	0.5	33
128	Effective Photoimmunotherapy of Murine Colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells. <i>Clinical Cancer Research</i> , 2004, 10, 4498-4508.	3.2	142
129	Differential influence of pentoxifylline on murine colon adenocarcinoma- and melanoma-derived metastatic tumor development in lungs. <i>Oncology Reports</i> , 2004, 11, 1121.	1.2	2
130	Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. <i>Oncology Reports</i> , 2004, 12, 1371-5.	1.2	11
131	Proteasome inhibitors in the treatment of cancer. <i>Drug Discovery Today</i> , 2003, 8, 575.	3.2	0
132	Natural mechanisms protecting against cancer. <i>Immunology Letters</i> , 2003, 90, 103-122.	1.1	181
133	Antitumor Effects of Photodynamic Therapy Are Potentiated by 2-Methoxyestradiol. <i>Journal of Biological Chemistry</i> , 2003, 278, 407-414.	1.6	113
134	Potential antitumor effects of statins (Review). <i>International Journal of Oncology</i> , 2003, 23, 1055.	1.4	56
135	Pentoxifylline promotes development of murine colon adenocarcinoma-derived metastatic tumors in liver. <i>Oncology Reports</i> , 2003, 10, 1805.	1.2	2
136	Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycytidine treatment in L1210 leukemia and B16F10 melanoma models in mice. <i>Clinical Cancer Research</i> , 2003, 9, 3124-33.	3.2	31
137	Potential antitumor effects of statins (Review). <i>International Journal of Oncology</i> , 2003, 23, 1055-69.	1.4	74
138	Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. <i>Clinical Cancer Research</i> , 2003, 9, 5417-22.	3.2	46
139	A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index. <i>Oncology Reports</i> , 2002, 9, 991.	1.2	3
140	Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. <i>Oncology Reports</i> , 2002, 9, 199.	1.2	0
141	Discussion on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. <i>Gastroenterology</i> , 2002, 123, 1747.	0.6	10
142	Determination of Aldehyde Dehydrogenase (ALDH) Isozymes in Human Cancer Samples - Comparison of Kinetic and Immunochemical Assays. <i>Molecules</i> , 2002, 7, 896-901.	1.7	0
143	Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. <i>International Journal of Cancer</i> , 2002, 97, 746-750.	2.3	16
144	Stimulation of TNF-Î± production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - a novel immunomodulator with potential application in tumour immunotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 213-222.	1.1	4

#	ARTICLE	IF	CITATIONS
145	Augmented antitumor effects of combination therapy with TNP-470 and chemoimmunotherapy in mice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002, 128, 433-442.	1.2	6
146	Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia. <i>Clinical Cancer Research</i> , 2002, 8, 1265-70.	3.2	26
147	Immunomodulation by anticancer chemotherapy: More is not always better (Review). <i>International Journal of Oncology</i> , 2001, 18, 417-24.	1.4	16
148	Direct stimulation of macrophages by IL-12 and IL-18 â€” a bridge too far?. <i>Immunology Letters</i> , 2000, 72, 153-157.	1.1	31
149	Antitumor effects of the combination therapy with TNF- $\hat{\pm}$ geneâ€”modified tumor cells and interleukin 12 in a melanoma model in mice. <i>Cancer Gene Therapy</i> , 2000, 7, 1581-1590.	2.2	25
150	INTERLEUKIN 18â€”INTERFERON $\hat{\beta}$ INDUCING FACTORâ€”A NOVEL PLAYER IN TUMOUR IMMUNOTHERAPY?. <i>Cytokine</i> , 2000, 12, 332-338.	1.4	58
151	A Combination of Retinoic Acid and Proteasome Inhibitors for the Treatment of Leukemias Is Potentially Dangerous. <i>Blood</i> , 1999, 94, 1827-1828.	0.6	6
152	The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production. <i>Cancer Letters</i> , 1999, 147, 67-75.	3.2	9
153	Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. <i>International Journal of Cancer</i> , 1998, 77, 720-727.	2.3	39
154	Erythropoietin Prevents the Development of Interleukin-12â€”Induced Anemia and Thrombocytopenia But Does Not Decrease Its Antitumor Activity in Mice. <i>Blood</i> , 1998, 91, 4387-4388.	0.6	14
155	Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 1997, 2, 455-462.	2.2	21
156	Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor $\hat{\pm}$ in mice. <i>Cancer Immunology, Immunotherapy</i> , 1997, 45, 100-108.	2.0	63
157	Potential of the anti-tumor effect of actinomycin D by tumor necrosis factor $\hat{\pm}$ in mice: Correlation between in vitro and in vivo results. , 1996, 66, 374-379.		27
158	Potential of antitumor effects of tumor necrosis factor $\hat{\pm}$ and interferon $\hat{\beta}$ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. <i>Cancer Immunology, Immunotherapy</i> , 1995, 40, 315-321.	2.0	35
159	Antitumor effects of the combination therapy with TNF- $\hat{\pm}$ geneâ€”modified tumor cells and interleukin 12 in a melanoma model in mice. , 0, .		1
160	Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. <i>Oncology Reports</i> , 0, , .	1.2	1
161	IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells. <i>Oncology Reports</i> , 0, , .	1.2	1
162	Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma. <i>Oncology Reports</i> , 0, , .	1.2	3

#	ARTICLE	IF	CITATIONS
163	Potentiated antitumor effects of a combination therapy with a farnesyltransferase inhibitor L-744,832 and butyrate in vitro. <i>Oncology Reports</i> , 0, , .	1.2	0
164	Demethylating agent 5-aza-2'-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo. <i>Oncology Reports</i> , 0, , .	1.2	4